Updates are available Correction dated 2025-03-24
Click to view Correction: https://doi.org/10.1186/s40478-025-01981-6
-
Authors
Nath, Samir R.
Dasgupta, Aneesha
Dubey, Divyanshu
Kokesh, Eileen
Beecher, Grayson
Fadra, Numrah
Liewluck, Teerin
Pittock, Sean
Doles, Jason D.
Litchy, William
Milone, Margherita
-
Funding
Funding for this research was provided by:
CCaTS Team Science Pilot Award, Mayo Clinic
Small Grants Program Award and Discretionary Fund, Mayo Clinic
- License Information
-
More Information
Article History
Received: 10 November 2024
Accepted: 6 January 2025
First Online: 16 January 2025
Change Date: 16 March 2025
Change Type: Update
Change Details: The original online version of this article was revised: the author’s name Teerin Liewluck was incorrectly written as Teerin Liewuck and has been updated.
Change Date: 24 March 2025
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1186/s40478-025-01981-6
Declarations
:
: This study was approved by the Mayo Clinic Institutional Review Board (IRB#18-010637).
: All authors have reviewed and approved the final version of the manuscript and consent to its publication in Acta Neuropathologica Communications. The study was approved by the Mayo Clinic Institutional Review Board (IRB#18-010637).
: MM has received personal compensation for serving on a Scientific Advisory or Data Safety Monitoring board for Argenx on an unrelated topic and for serving as an Associate Editor for Neurology Genetics, AAN. SP has received personal compensation for consulting roles with Genentech, Sage Therapeutics, Prime Therapeutics, UCB, Roche/Genentech, and Arialys Therapeutics, as well as for serving on a Scientific Advisory or Data Safety Monitoring board for UCB, Inc., Genentech, and F. Hoffman/LaRoche, for advisory work with Hoffman/LaRoche AG and Alexion, for consulting roles with Astellas, Alexion, MedImmune/Viela Bio, and Roche/Genentech. His institution has received research support from Grifols, NIH, Viela Bio/MedImmune/Horizon, Alexion Pharmaceuticals, F. Hoffman/LaRoche/Genentech, NovelMed, and AstraZeneca. SP holds intellectual property interests in healthcare-related discoveries and technologies. D.D. has consulted for UCB, Immunovant, Argenx, Arialys and Astellas pharmaceuticals. All compensation for consulting activities is paid directly to Mayo Clinic. He is a named inventor on filed patent that relates to KLHL11 as marker of autoimmunity and germ cell tumor. He has patents pending for LUZP4-IgG, cavin-4-IgG and SKOR2 IgG as markers of neurological autoimmunity. He has received funding from the DOD (CA210208 & PR220430), David J. Tomassoni ALS Research Grant Program and UCB.
